AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.08 · Revenue $83.98M · 2 analysts
Est. EPS $-0.06 · Revenue $83.69M · 1 analysts
Est. EPS $-0.27 · Revenue $337.40M · 2 analysts
Est. EPS $-0.04 · Revenue $355.17M · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $320.2M | +9.5% | +10.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-36.7M | -8.1% | -41.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +54.6% | +1.3% | +7.9% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -12.5% | +8.7% | -186.7% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -11.5% | +1.3% | -27.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $508000 | +103.5% | +513.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +0.2% | +103.2% | +474.0% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.0% | -100.0% | -100.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.19x | -1.0% | -7.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $267.2M | -4.6% | +2.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.88 vs -0.16 | -443.9% | -0.28 vs -0.09 | -212.2% |
| Revenue Surprise | $320.2M vs $314.1M | +1.9% | $86.6M vs $80.2M | +7.9% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Nighan Warren JR | officer: SVP Quality and Regulatory | Common Stock | D | 23,370 | $14.72 |
| Jul 22, 2026 | Piccinini Laura | officer: SVP International | Common Stock | A | 8,047 | — |
| Jul 22, 2026 | Piccinini Laura | officer: SVP International | Common Stock | D | 4,506 | $13.82 |
| Jul 22, 2026 | Piccinini Laura | officer: SVP International | Performance Right | D | 28,336 | — |
| Jul 22, 2026 | Nighan Warren JR | officer: SVP Quality and Regulatory | Common Stock | A | 5,694 | — |
Operator: Good morning, and welcome to the AngioDynamics fiscal year 2026 fourth quarter and full year earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference call is being recorded. The news release detailing AngioDynamics fiscal 2026 fourth quarter and full year results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the internet at the investors section of the company website at www.angiodynamics.com. A webcast replay of the call will be available at the same site approximately one hour after the end of today's call. Before we begin, I'd like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings, and gross margin for fiscal year 2027, as well as trends that may continue. Management encourages you to review the company's past and future filings with the SEC, including, without limitation, the company's Forms 10-Q and 10-K, which identify specific factors that may cause the actual results or events to differ materially from those described in the forward-looking statements. The company will also discuss certain non-GAAP and pro forma financial measures during this call. Management uses these measures to establish operational goals and review operational performance and believes that these measures may assist investors in analyzing the underlying trends in the company's business over time. Investors should consider these non-GAAP and pro forma measures in addition to, not a substitute for, or as superior to, financial reporting measures prepared in accordance with GAAP. A slide package offering insight into the company's financial results is also available in the investors section of the company's website under events and presentations. This presentation should be read in conjunction with the press release discussing the company's operating results and financial performance during this morning's conference call. Unless otherwise noted, all metrics and growth rates mentioned during today's call are on a pro forma basis, which exclude the results of the Dialysis and BioSentry businesses that were divested in June 2023, the PICC and Midline products that were also divested in February 2024, and the RadioFrequency and Syntrax support catheter products that we discontinued in February 2024. Also, unless otherwise noted, all comparisons will be the fourth fiscal quarter of 2026 versus the fourth fiscal quarter of 2025, and the full fiscal year 2026 versus the full fiscal year of 2025. Now, I would like to turn the call over to Jim Clemmer, AngioDynamics President and Chief Executive Officer. Mr. Clemmer? Jim Clemmer: Thank you, and good morning, everyone, and thank you for joining us for …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
James C. Clemmer | Chief Executive Officer, President & Director | USD 2,057,207 | Male | 1964 | Active |
Stephen A. Trowbridge | Executive Vice President & Chief Financial Officer | USD 940,215 | Male | 1974 | Active |
Laura Piccinini | Senior Vice President & GM of Cardiovascular and International | USD 842,301 | Female | 1969 | Active |
Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | USD 739,569 | Male | 1969 | Active |
Lawrence T. Weiss | Senior Vice President, Chief Legal Officer & Corporate Secretary | USD 696,577 | Male | 1970 | Active |
Chad T. Campbell | Senior Vice President and GM of Oncology & Interventional Devices | USD 592,757 | Male | 1971 | Active |
Jake Brumbaugh | Global Vice President for Marketing-Oncology | — | Male | — | Active |
Saleem Cheeks | Vice President of Communications | — | Male | — | Active |
Marna I. Bronfen-Moore | Senior Vice President of Human Resources | — | Female | 1968 | Active |
Kim L. Seabury | Senior Vice President of Information Technology | — | Female | 1968 | Active |
Juan Carlos Serna | Senior Vice President of Scientific & Clinical Affairs | — | Male | — | Active |
Benjamin H. Davis | Senior Vice President of Business Development & Strategy | — | Male | 1964 | Active |
Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 503,640 shares of the medical instruments supplier's stock after purchasing an additional 364,763
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.
